Medicines for Malaria Venture new developments in antimalarials

Travel Medicine and Infectious Disease

Volumn 2, Issue 3-4, 2004, Pages 161-170

  Nwaka, Solomon ^a   Riopel, Lise ^a   Ubben, David ^a   Craft, J Carl ^a  

^a Medicines for Malaria Venture   (Switzerland)

Author keywords

Chemoprophylaxis; Drug discovery and development; Malaria chemotherapy; MMV; Plasmodium falciparum and vivax; Public private partnerships; Uncomplicated malaria

Indexed keywords

2,5 BIS(4 AMINOPHENYL)FURAN; 8 AMINOQUINOLINE DERIVATIVE; ACRIDINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTEMISONE; ARTESUNATE; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; DB 289; DIAMIDINE DERIVATIVE; DIHYDROARTEMISININ; DIHYDROFOLATE REDUCTASE INHIBITOR; DOXYCYCLINE; FANSIDAR; FURAN DERIVATIVE; HEMATIN; ISOQUINE; PENTAMIDINE; PIPERAQUINE; PRIMAQUINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYONARIDINE; PYRIDONE DERIVATIVE; QUINIDINE; QUININE; RBX 11160; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COOPERATION; DEATH; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; ENDEMIC DISEASE; FINANCIAL MANAGEMENT; GOOD MANUFACTURING PRACTICE; HEALTH CARE ORGANIZATION; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION CONTROL; INJECTION PAIN; MALARIA FALCIPARUM; MEDICAL DECISION MAKING; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; TOOTH DISEASE; TRAVEL;

EID: 4544363721     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2004.03.002     Document Type: Article

References (27)

1. Trouiller P. Olliaro P. White N. et al. Drugs for neglected diseases: a failure of the market and public health failure Trop Med Int Health 6 2001 945-951
2. Nwaka S. Ridley R. Virtual drug discovery and development for neglected diseases through public-private partnerships Nat Rev Drug Discov 2 2003 919-928
3. MMV Annual Report 2002
4. MMV Business Plan 2003
5. MMV 4th call for letters of interest. Science 2004; 303:905
6. Wellems T. Plowe C. Chloroquine-resistant malaria J Infect Dis 184 2001 770-776
7. Sirawaraporn W. Dihydrofolate reductase and antifolate resistance in malaria Drug Resist Update 1 1998 397-406
8. White N.J. Delaying antimalarial drug resistance with combination therapy Parasitologia 41 1999 301-308
9. White N.J. Preventing antimalarial drug resistance through combinations Drug Resist Updates 1 1998 3-9
10. Antimalarial drug combination therapy. Report of a WHO technical consultation; 2001
11. Winstanley P. Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria Trop Med Int Health 6 2001 952-954
12. Lang T. Greenwood B. The development of Lapdap, an affordable new treatment for malaria Lancet Infect Dis 3 2003 162-168
13. Yeramian P. Krudsood S. Chalemrut K. et al. Efficacy of DB289 in acute uncomplicated P. Falciparum/P. vivax malaria ASTMH, 52 Annual Meeting Philadelphia 2003 Poster number 2046
14. Gordi T. Lepist E.I. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 147 2004 99-107
15. Ringwald P. Bickii J. Basco L.K. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children Clin Infect Dis 26 1998 946-953
16. Ringwald P. Bickii J. Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa Lancet 347 1996 24-28
17. Vennerstrom JL, Dong Y, Chollet J, Spiro and dispiro 1,2,4-trioxolanes antimalarials. US patent 6,486,199 field; 2002
18. Tran T.H. Dolecek C. Pham P.M. et al. Dihydroartemisinin-piperaquine against multi-drug-resistant P. falciparum malaria in Vietnam: randomized clinical trial Lancet 363 2004 18-22
19. Gelb M.H. Van Voorhis W.C. Buckner F.S. et al. Protein farnesyltransferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatids and antimalarial therapeutics Mol Biochem Parasitol 126 2003 155-163
20. Stead A.M.W. Bray P.G. Edwards I.G. et al. Diamidine compounds: selective uptake and targeting in P. falciparum Mol Pharmacol 59 2002 1298-1306
21. Rieckman K.H. et al. effect of tetracycline against chloroquine-resistance and chloroquine sensitive P. falciparum Am J Trop Med Hyg 20 1971 811-815
22. Lochary M.E. Lockhart P.B. Jr William W.T. Doxycycline and staining of permanent teeth Pediatr Infect Dis J 17 1998 429-431
23. Yuvaniyama J. Chitnumsub P. Kamchonwongpaisan S. et al. Insight into antifolate resistance from malarial DHFR-TS structures Nat Struct Biol 10 2003 357-365
24. Rosenthal P.J. Sijwali P.S. Singh A. et al. Cysteine proteases of malaria parasites: targets for chemotherapy Curr Pharm Des 8 2002 1659-1672
25. Rao S.P. Surolia A. Surolia N. Triclosan: a shot in the arm for antimalarial chemotherapy Mol Cell Biochem 253 2003 55-63
26. Kuo M.R. Morbidoni M.R. Alband D. et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structure data J Biol Chem 278 2003 20851-20859
27. Rao K.V. Santarsiero B.D. Mesecar A.D. Schinazi R.F. Tekwani B.L. Hamann M.T. New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge J Nat Prod 66 2003 823-828